Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 108B 391M 335M 313M 287M 540M 37.35B 549M 3.69B 1.45B 18.73B 1.47B 1.44B 61.94B P/E 2026 *
9.88x
P/E 2027 * 8.43x
Enterprise Value 108B 391M 335M 313M 287M 540M 37.35B 549M 3.69B 1.45B 18.73B 1.47B 1.44B 61.94B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.45x
Free-Float
-
Yield 2026 *
5.4%
Yield 2027 * 6.11%
08-02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
08-02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
05-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
04-06 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
03-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
03-26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-24 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-0.81%
1 week-1.44%
Current month-1.51%
1 month-4.84%
3 months+2.82%
6 months-11.49%
Current year-12.66%
1 week 340
Extreme 340
349.99
1 month 337.5
Extreme 337.5
361.75
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2011-05-06
Director/Board Member - 2018-12-04
Director/Board Member 72 2020-04-01
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-1.44%-20.74%+340.41% 394M
+4.46%+4.92%+82.07%+134.31% 1,093B
+0.85%+4.81%+53.77%+58.51% 653B
+2.72%+6.92%+28.99%+77.15% 458B
+1.80%+0.52%+41.20%+44.05% 355B
+1.24%+2.35%+25.99%+42.21% 294B
+2.07%+2.97%+2.27%+13.06% 248B
+4.02%+6.29%+49.67%+68.96% 230B
+1.05%-0.02%-13.96%-52.13% 203B
+2.90%+8.63%+25.11%+94.52% 178B
Average +1.65%+2.67%+27.44%+82.10% 371.09B
Weighted average by Cap. +1.53%+3.65%+46.87%+73.77%

Financials

2026 *2027 *
Net sales 68.81B 248M 213M 199M 182M 343M 23.71B 348M 2.34B 918M 11.89B 931M 911M 39.31B 74.58B 269M 231M 215M 198M 371M 25.69B 378M 2.54B 995M 12.89B 1.01B 987M 42.61B
Net income 10.49B 37.81M 32.43M 30.29M 27.79M 52.25M 3.61B 53.11M 357M 140M 1.81B 142M 139M 5.99B 12.42B 44.77M 38.4M 35.86M 32.9M 61.87M 4.28B 62.89M 423M 166M 2.15B 168M 164M 7.1B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-08-19 PKR 340.44 -0.81% 194,033
26-08-18 PKR 343.21 -0.58% 159,489
26-08-17 PKR 345.21 +0.15% 99,357
26-08-13 PKR 344.70 -0.21% 72,717
26-08-12 PKR 345.43 +0.14% 63,596
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
340.44PKR
Average target price
510.00PKR
Spread / Average Target
+49.81%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock